Purpose: The aim of the study is to evaluate the association between genetic polymorphisms and valproic acid (VPA) concentration to dose ratio in children with epilepsy on VPA monotherapy. Methods: A total of 137 children, aged 3.5-18 years, (89 males and 48 females) with epilepsy on sustainedrelease VPA monotherapy were enrolled. Trough plasma concentrations of VPA at steady-state were measured using an AXSYM automatic immunity analyzer. The values were divided by body weight and total daily dose to calculate concentration to dose ratio of VPA (CDRV). Forty-eight single nucleotide polymorphisms involved in the pharmacokinetics of VPA were identified by MassARRAY system. The logarithmic transformed CDRV (lnCDRV) was normally distributed, and PLINK software was used to evaluate the association between genetic polymorphisms and lnCDRV using linear regression adjusted for gender and seizure type. Results: rs28898617 (UGT1A3/4/5/6/7/8/9/10, BETA = 0.32, P = 0.0089) was significantly associated with higher lnCDRV. No other associations were found. Conclusions: In pediatric patients taking VPA monotherapy, rs28898617 was associated with a higher normalized VPA plasma concentration. Further studies are warranted to confirm the results.
Introduction
Epilepsy greatly affects a patient's longevity and quality of life and has high morbidity in children. Valproic acid (VPA) has been used for more than 50 years to treat various types of seizures in children and adults [1] . In clinical practice the plasma concentration and the efficacy of VPA varies greatly between individuals [2] . Many factors such as age, body weight, total daily dose, dosage form, dosing frequency, sampling time, concomitant antiepileptic medications, diet and genetic variations involved in the pharmacokinetics of VPA are correlated with VPA plasma concentration [2] [3] [4] [5] [6] [7] [8] .
VPA is a fatty acid and can be absorbed by fatty acid binding proteins, and the effective dose of VPA depends on the polymorphisms of fatty acid binding protein 2 (FABP2, 163 G > A) [9] . To enter the brain and produce physiological action, VPA may use various transporters such as ATP binding cassette subfamily B member 1, and genetic variants in these transporters may influence its plasma concentration and efficacy [10, 11] . Glucuronidation and mitochondrial b-oxidation are two major pharmacokinetic pathways in adult patients on VPA monotherapy [12] .
Abbreviations: VPA, valproic acid; FABP2, fatty acid binding protein 2; UGT1A6, uridine diphosphate glucuronosyltransferase family 1 member A6; UGT2B7, uridine diphosphate glucuronosyltransferase family 2 member B7; CYP2C9, cytochrome P450 family 2 subfamily C member 9; CYP2A6, cytochrome P450 family 2 subfamily A member 6; CYP2B6, cytochrome P450 family 2 subfamily B member 6; GABA, gamma-aminobutyric acid; CDRV, concentration to dose ratio of valproic acid; lnCDRV, logarithmic transformed CDRV; MAF, minor allele frequency; HWE, HardyWeinberg equilibrium; BETA, regression coefficients; STAT, coefficient T-statistic; UGT1A3/4/5/6/7/8/9/10, uridine diphosphate glucuronosyltransferase family 1 member A 3/4/5/6/7/8/9/10; CYP, cytochrome P450; CYP2C19, cytochrome P450 family 2 subfamily C member 19. Variants in glucosidases such as uridine diphosphate glucuronosyltransferase family 1 member A6 (UGT1A6) and uridine diphosphate glucuronosyltransferase family 2 member B7 (UGT2B7) are associated with VPA plasma concentration [4, 8, 13] . Cytochrome P450 family 2 subfamily C member 9 (CYP2C9) is a major contributor to the formation of 4-ene-VPA, 4-OH-VPA, and 5-OH-VPA, whereas cytochrome P450 family 2 subfamily A member 6 (CYP2A6) and cytochrome P450 family 2 subfamily B member 6 (CYP2B6) have small contributions [6] . Moreover, clinical studies have widely reported the effects of CYP2A6 and CYP2C9 on VPA metabolism [2, 5] .
The mechanism of the anticonvulsant activity of VPA has been theorized to be due to the increased level of gamma-aminobutyric acid (GABA) due to the inhibition of VPA on GABA transaminase, which is encoded by 4-aminobutyrate aminotransferase gene [1, 14] . VPA targets the GABA receptor, positively regulates the receptors, and enhances GABA receptor-mediated inhibition [15] . Blocking voltage-gated calcium channels encoded by the sodium voltage-gated channel gene family reduces the high-frequency of neurons firing which may be also involved in the anticonvulsant activity of VPA [15] . Moreover, VPA could affect the neuronal excitation that is mediated by the N-methyl-D-aspartate subtype of glutamate receptors encoded by the glutamate ionotropic receptor N-methyl-D-aspartate type gene family [1] .
To determine genetic predictors for dose adjustment in the treatment of children with epilepsy, pediatric patients taking sustained-release tablets of VPA with a dosing frequency of twice a day for at least 30 days were enrolled in this clinical study. To minimize the inter-individual pharmacokinetic variations, trough steady-state plasma concentrations of VPA were measured and divided by body weight and total daily dose to determine the concentration to dose ratio of VPA (CDRV, mg/L per g/kg/day) [8, 16] . Drug-drug interactions are important for VPA because of their significant effect on its metabolism [17] . Additionally, fooddrug interactions also influence the pharmacokinetics of VPA. For example, soybean intake can greatly decrease the plasma concentration of VPA [18] .
The distribution of CDRV data should be normal in association analysis. The CDRV was abnormally distributed so logarithmic transformation was performed to obtain logarithmic transformed CDRV (lnCDRV) with a normal distribution. Based on previous studies and the PharmGKB database [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] 13, 16, [19] [20] [21] [22] [23] [24] [25] [26] , various genetic polymorphisms involved in the pharmacokinetics of VPA were identified. The association between the genetic variants and lnCDRV was analyzed, and one polymorphism in the uridine diphosphate glucuronosyltransferase gene family was associated with a higher normalized VPA plasma concentration.
Methods

Study design
This study was approved by the Ethics Committee of Beijing Tiantan Hospital, Capital Medical University, Beijing, China. All patients were Chinese ethnicity. Signed informed consent of patients was obtained from patients of their direct relatives. The inclusion criteria was as follows: (1) patients had a diagnosis of epilepsy [27] , (2) aged 2 to 18 years, (3) regularly receiving sustained-release tablets of VPA twice a day for at least 30 days, (4) without taking other antiepileptic drugs, (5) without other serious diseases. Exclusion criteria were severe liver, renal or cardiac impairment, and serious adverse drug reactions to VPA.
A total of 137 children (14 inpatients and 123 outpatients) on VPA treatment in Beijing Tiantan Hospital were enrolled. Patients were enrolled according to the above criteria. Patients' demographic data (gender, age, and body weight), dosage regimen (dose and frequency) and seizure type (generalized seizures, focal seizures and unclassified seizures) [28] were recorded. After regularly taking sustained-release tablets of VPA twice a day for at least 30 days, steady-state trough blood samples were collected 2 h prior to the next dose. After centrifugation at 5000 Â g for 10 min at room temperature, the plasma was used to evaluate the VPA concentration on an AXSYM automatic immunity analyzer, and the white blood cells were stored at À80 C for genotyping by the MassArray method [29] . To ensure analytic quality, 5% of patients were measured repeatedly and the reproducibility was acceptable.
Plasma concentration of VPA
The total plasma concentrations of VPA were analyzed on an AXSYM automatic immunity analyzer (TDx, ABBOTT, USA) by fluorescence polarization immunoassay. Routine calibration curve and quality control samples were applied to ensure the accuracy and precision of the method, and the results were acceptable. To minimize the inter-individual variations, the plasma concentrations of VPA were divided by total daily dose and body weight to obtain CDRV [16] .
Genotyping
Genetic polymorphisms for examination were chosen based on previous studies and the PharmGKB database [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] 13, 16, [19] [20] [21] [22] [23] [24] [25] [26] . The minor allele frequency (MAF) of the selected variants was 5% or greater in Han Chinese (data from 1000 Genomics databases). The white blood cells of collected samples were used for genotyping. Patients' DNA were isolated by QIAamp DNA purification kit (Qiagen, Hilden, Germany). Genotyping was performed by Bio Miao Biological Technology (Beijing) by MassArray method (Sequenom, USA) [29] .
Statistical analysis
Statistical analysis was carried out by SPSS (version 17.0, SPSS Inc., Chicago, USA) and PLINK (version 1.07, Shaun Purcell, Boston, USA) software. The distribution of CDRV was evaluated and logarithmic transformation of CDRV to lnCDRV was used when CDRV was abnormally distributed. Continuous variables were expressed as mean AE SD and statistically treated by student's t-test or nonparametric test. The chi-square test was used to analyze classified variables. Prior to association analysis, the normality test indicated that the CDRV was abnormally distributed. After logarithmic transformation, the lnCDRV was normally distributed. The associations between lnCDRV and genetic polymorphisms were evaluated by PLINK software using linear regression adjusted for gender and seizure type. For all selected alleles, the MAF, genotype, Hardy-Weinberg Equilibrium (HWE) (P-value, chisquare test), regression coefficients (BETA), coefficient T-statistic (STAT), and P values (asymptotic P value for T-statistic) were calculated. Statistical significance was regarded as P-value < 0.05.
Results
Characteristics of enrolled patients
A total of 137 children with epilepsy were enrolled (48 females and 89 males). The characteristics of enrolled patients are summarized in Table 1 
Genotyping and its association with lnCDRV
All of the selected variants were consist with the HWE except rs1048943 (P = 0.040). Only one variant, rs28898617 (uridine diphosphate glucuronosyltransferase family 1 member A 3/4/5/ 6/7/8/9/10, UGT1A3/4/5/6/7/8/9/10, A > G), was significantly associated with higher lnCDRV (BETA = 0.32, P = 0.0089).
Discussion
Association between genetic variants and lnCDRV
FABP2 exists mainly in the small intestine cells, which are involved in the absorption of many fatty acids [9] . The chemical structure of VPA is similar to that of fatty acids, and its effective dose is affected by FABP2 variants in Russians (163 G > A) [9] . rs1799883 (163 A > G, MAF = 0.322) is a missense variant of FABP2 in exon with a definite effect on protein structure, and seems to alter the enzyme activity [8] . However we failed to find an association between this variant and lnCDRV.
The Uridine diphosphate glucuronyl transferase family is widely involved in VPA metabolism, 30-50% of the total VPA dose is excreted as VPA-glucuronide conjugate [12] . rs28898617 (17 A > G), a variant in UGT1A3/4/5/6/7/8/9/10 (Gln > Arg) genes, was significantly associated with a higher lnCDRV (BETA = 0.32, P = 0.0089). The lack of reports about this variant might be due to its extremely low MAF in humans (0.010, data from the 1000 genomes database), and because this variant exists primarily in East Asian populations (0.058 in our patients). The finding in the present study was consistent with our previous result in children taking VPA oral solution. [25] Furthermore, bessiy constructing five expron models and using estrone as substrate, a study of 100 healthy Japanese adults found that this variant changed the UGT1A3 efficiency (Km/Vmax) to 86% of wild type [23] . This might decrease the glucuronidation of VPA and subsequently increase its plasma concentration. rs6759892 (T > G, UGT1A6, MAF = 0.260) and rs1105879 (A > C, UGT1A6*9, MAF = 0.262) are two missense mutations in exon, and both result in an increased enzyme activity [8, 20, 30] . These two variants could affect VPA metabolism, therefore carriers may need an increased VPA dose [8, 20] . Other variants of UGT1A6 with high MAF were also selected for evaluation, but none of them were associated with lnCDRV.
Two studies have indicated that rs28365063 is associated with increased activity of UGT2B7, resulting in a lower lnCDRV [31, 32] . One study found that UGT2B7*1a (including this variant) is associated with an increased enzyme activity and mRNA expression in human livers [31] . The other indicated that rs28365063 is associated with a greater carbamazepine clearance in an AfricanAmerican cohort [32] . rs28365063 is a synonymous variant, its exact effect on enzyme activity may be derived from its wide linkage disequilibrium with other variants.
A missense variant of UGT2B7, rs7439366 (C > T, UGT2B7*2), is located in exon with the amino acid changing from Tyr to His. The C allele is the major allele in Han Chinese (MAF = 0.722) and Japanese populations (MAF = 0.682), but in northern and western European populations the T and C allele have the same frequency (MAF = 0.50, data from the 1000 Genomes database). rs7439366 might influence UGT2B7 activity, but in previous studies, the activity changes were contradictory [20, 21, 33] and the influence of rs7439366 on VPA pharmacokinetics in patients with epilepsy was inconsistent [16, 19, 22, 26] . Most studies indicated that CC carriers had lower normalized plasma VPA concentrations than those with CT or TT genotypes [19, 22, 26] . However, a recent study suggested that T carriers may need an increased VPA dose to achieve the therapeutic range (50-100 mg/mL) in Chinese patients with epilepsy [16] . Twelve polymorphisms in UGT2B7 were identified, but none of them were associated with lnCDRV.
In adult patients on VPA monotherapy, glucuronidation and mitochondrial b-oxidation are two major pathways in VPA metabolism. Approximately 15-20% of the total VPA dose is metabolized by CYP2C9, CYP2A6 and CYP2B6 [6, 24] . However, Budi, T. et al. [3] proposed that Cytochrome P450 (CYP) enzymes are more important in children than in adults for VPA metabolism for the following reasons: the expression of uridine 5 0 -diphosphate-glucuronyl transferases (involved in VPA glucuronidation) is lower in children than in adults [34, 35] ; mitochondrial b--oxidation can be inhibited by VPA and its metabolites [36, 37] ; CYP activities are higher in children than in adults, but reduce to adult levels by puberty [38, 39] . Furthermore, they found that the CYP2C9-status guided VPA therapy in children resulted in reduced VPA misdosing and the avoidance of misdosing-induced side effects [3] .
In previous studies, rs1057910 (1075 A > C, CYP2C9*3) was associated with decreased enzyme activity [40, 41] and increased VPA plasma concentrations [2, 3, 5, 6] . The MAF of this important variant was 0.051 in our patients but an association with lnCDRV was not found, which is consistent with another study in 98 Chinese children with epilepsy on VPA monotherapy [4] . CYP2B6 is involved in VPA metabolism in vitro and may influence the lnCDRV in vivo [5, 6] . For rs2279343 (CYP2B6*4), a missense variant of CYP2B6, the protein expression in CYP2B6*4 carriers was rather low, but the difference did not reach significance compared to the wild-type carriers [42] . However, another study on 121 healthy male volunteers indicated that the enzyme activity (represented by the clearance of bupropion) in CYP2B6*4 carriers was 1.66-fold higher compared to the wild-type carriers (P = 0.001) [43] . rs28399433 (CYP2A6*9), a variant in the promoter region of CYP2A6 gene, reduced mRNA and protein expression levels in human livers [44, 45] . Five variants in CYP2C9, CYP2A6 and CYP2B6 were identified in the present study, yet none of them were associated with lnCDRV. Table 1 Clinical characteristics of enrolled patients with epilepsy taking VPA (sustained-release tablets) monotherapy twice a day (n = 137).
Variable
Enrolled patients (n = 137) rs4986893 (G > A, Cytochrome P450 family 2 subfamily C member 19*3, CYP2C19*3) is an important mutation in East Asian populations with an MAF of 0.047 in our patients. This variant can stop protein translation and result in nonfunctional protein expression, thereby dramatically influencing the metabolism of drugs such as clopidogrel [46] . Although the undergoing mechanism of CYP2C19 on VPA metabolism is still unclear, rs4986893 significantly decreased the clearance of VPA in a population pharmacokinetic study in Chinese patients with epilepsy [2] . rs4244285 (G > A, CYP2C19*2) is another important mutation of CYP2C19 with an MAF of 0.34 in our study. This mutation can also lead to nonfunctional protein expression and may affect drug metabolism [2, 47] . However, neither of the two variants was significantly associated with lnCDRV in our study, which indicates that CYP2C19 may not the major factor in VPA metabolism.
Deficiencies of the study
Limitations of the study include: (1) the sample size was relatively small (137 patients); (2) despite their influence on VPA metabolism, many variants were not selected due to low frequency in the population (MAF < 0.05) [7, 20] ; (3) possible influence of food-drug interactions on VPA plasma concentration was not evaluated [18] .
Conclusions
In pediatric patients taking VPA monotherapy, normalized VPA plasma concentration was associated with a genetic polymorphism in UGT1A3/4/5/6/7/8/9/10 genes. Further studies are warranted to confirm the results.
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